MgCaCO3 Versus CaCO3 in Peritoneal Dialysis Patients – a Cross-over Pilot Trial
| Autor: | Babak Aliazardeh, Elena Sze, Gursarn Bajwa, Irene Liu, Baigalmaa Evsanaa, Paul Tam, Sara Mahdavi, Jerry Gula, Tabo Sikaneta, Michelle Tam, Janet Roscoe |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male medicine.medical_specialty Constipation medicine.medical_treatment Population Administration Oral chemistry.chemical_element Pilot Projects Calcium Risk Assessment Gastroenterology Drug Administration Schedule Calcium Carbonate Peritoneal dialysis chemistry.chemical_compound Internal medicine medicine Humans Magnesium Single-Blind Method education Adverse effect Dialysis Aged education.field_of_study Cross-Over Studies Dose-Response Relationship Drug business.industry Original Articles General Medicine Middle Aged Phosphate Surgery Hyperphosphatemia Treatment Outcome chemistry Nephrology Patient Compliance Female medicine.symptom business Peritoneal Dialysis Follow-Up Studies |
| Zdroj: | Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis. 35:31-34 |
| ISSN: | 1718-4304 0896-8608 |
| DOI: | 10.3747/pdi.2013.00129 |
| Popis: | Background Despite adverse effects such as constipation, vascular calcification, and hypercalcemia, calcium-based salts are relatively affordable and effective phosphate binders that remain in widespread use in the dialysis population. We conducted a pilot study examining whether the use of a combined magnesium/calcium-based binder was as effective as calcium carbonate at lowering serum phosphate levels in peritoneal dialysis (PD) patients. Methods This was a cross-over, investigator-masked pilot study in which prevalent PD patients received calcium carbonate alone (200 mg calcium per tablet) or calcium magnesium carbonate (100 mg calcium, 85 mg magnesium per tablet). Primary outcome was serum phosphate level at 3 months. Analysis was as per protocol. Results Twenty patients were recruited, 17 completed the study. Mean starting dose was 11.35 ± 7.04 pills per day of MgCaCO3 and 9.00 ± 4.97 pills per day of CaCO3. Mean phosphate levels fell from 2.13 mmol/L to 2.01 mmol/L (95% confidence interval (CI): 1.76 – 2.30, p = 0.361) in the MgCaCO3 group, and 1.81 mmol/L (95% CI: 1.56 – 2.0, p = 0.026) in the CaCO3 alone group. Six (35%) patients taking MgCaCO3 and 9 (54%) taking CaCO3 alone achieved Kidney Disease Outcomes Quality Initiative (KDOQI) serum phosphate targets at 3 months. Diarrhea developed in 9 patients taking MgCaCO3 and 3 taking CaCO3. Serum magnesium exceeded 1.4 mmol/L in 5 patients taking MgCaCO3 while serum calcium exceeded 2.65 mmol/L in 3 patients receiving CaCO3. When compared to the initial dose, the prescribed dose at 3 months was reduced by 44% (to 6.41 tablets/day) in the MgCaCO3 group and by 8% (to 8.24 pills per day) in the CaCO3 alone group. Conclusion Compared with CaCO3 alone, the preparation and dose of MgCaCO3 used in this pilot study was no better at lowering serum phosphate levels in PD patients, and was associated with more dose-limiting side effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|